Prosonix is an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design. Prosonix’ ultrasonic particle engineering technology enables it to design and engineer mono and combination drug particles that precisely meet the specific requirements for inhalation, delivering assured formulation performance using simple, cost-effective devices for a range of generic, super-generic and novel products. Prosonix’ pipeline focuses on near, mid and long-term opportunities, including: • PSX1001/PSX1050, a directly substitutable generic version of fluticasone propionate, a potent inhaled corticosteroid monotherapy for asthma and chronic obstructive pulmonary disease (COPD) in pressurised metered dose inhaler (pMDI) •PSX1002, a drug-only proprietary formulation of glycopyrronium bromide, a long-acting muscarinic antagonist for COPD in pMDI • PSX2005, a directly substitutable generic version ICS/LABA combination in pMDI • PSX2000 Novel combination medicines designed specifically for respiratory diseases based on Multi-component Particles™ (MCPs™). Prosonix has raised more than £20M from experienced life sciences investors to date.
Looking for a particular Prosonix Ltd employee's phone or email?
Prosonix Ltd Questions
The Prosonix Ltd annual revenue was $7.4 million in 2026.
Prosonix Ltd is based in Oxford, Oxfordshire.
The NAICS codes for Prosonix Ltd are [3254, 325, 32, 32541].
The SIC codes for Prosonix Ltd are [28, 283, 2834].
